Skip to main content
Erschienen in: Pediatric Drugs 1/2010

01.06.2010 | Review Article

Appropriate Treatment of Acute Otitis Media in the Era of Antibiotic Resistance

verfasst von: Professor Ron Dagan

Erschienen in: Pediatric Drugs | Sonderheft 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The outcome of treatment for acute otitis media (AOM) differs between various antibiotic drugs. Outcome depends upon the drugs’ pharmacokinetics, but in the case of infectious diseases also on the susceptibility of the organism and the interaction between the drug and the organisms at the specific site of infection (pharmacodynamics). In the era of antibiotic resistance, it is thus important to understand the pharmacokinetics/pharmacodynamics of the various available drugs in the context of AOM and its main two pathogens, Streptococcus pneumoniae and non-typeable Haemophilus influenzae. In terms of clinical outcome, it is also important to realize that AOM is a self-limiting disease in most cases, so that response to treatment is always compared with the expected background response when not treated. A favourable clinical outcome (cure/improvement) at the end of the treatment period is expected for those in whom the pathogens are eradicated within 3–5 days, thus clinical failure rates are several fold lower in children with early eradication (within 3–5 days) compared with those in whom no early eradication takes place. Because of the higher spontaneous bacterial elimination this might not always be appreciated. In this review, the relationship between antibiotic resistance, the various antibiotic drugs and their pharmacokinetic/pharmacodynamic patterns, the bacteriological outcome and clinical outcomes are addressed. This review is meant to assist the clinician in both a better understanding of the current recommendations for the treatment of AOM and the steps to be taken to follow AOM patients.
Literatur
1.
Zurück zum Zitat Pelton SI. New concepts in the pathophysiology and management of middle ear disease in childhood. Drugs 1996; 52: 62–6PubMedCrossRef Pelton SI. New concepts in the pathophysiology and management of middle ear disease in childhood. Drugs 1996; 52: 62–6PubMedCrossRef
2.
Zurück zum Zitat Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002; 2: 593–604PubMedCrossRef Dagan R, Leibovitz E. Bacterial eradication in the treatment of otitis media. Lancet Infect Dis 2002; 2: 593–604PubMedCrossRef
3.
Zurück zum Zitat Craig W, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255–9PubMedCrossRef Craig W, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255–9PubMedCrossRef
4.
Zurück zum Zitat Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine, 3rd edn. Baltimore, MD, USA: Williams & Wilkins, 1999: 403–31 Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine, 3rd edn. Baltimore, MD, USA: Williams & Wilkins, 1999: 403–31
5.
Zurück zum Zitat Leibovitz E, Raiz E, Piglansky L, et al. Resistance pattern ofmiddle ear fluid in acute otitis media. Pediatr Infect Dis J 2004; 23: 1142–55PubMed Leibovitz E, Raiz E, Piglansky L, et al. Resistance pattern ofmiddle ear fluid in acute otitis media. Pediatr Infect Dis J 2004; 23: 1142–55PubMed
6.
Zurück zum Zitat Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23: 829–33PubMedCrossRef Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004; 23: 829–33PubMedCrossRef
7.
Zurück zum Zitat Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004; 23(9): 824–8PubMedCrossRef Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004; 23(9): 824–8PubMedCrossRef
8.
Zurück zum Zitat Segal N, Givon Lavi N, Leibovitz E, et al. Acute otitis media caused by Streptococcus pyogenes in children. Clin Infect Dis 2005; 41: 35–41PubMedCrossRef Segal N, Givon Lavi N, Leibovitz E, et al. Acute otitis media caused by Streptococcus pyogenes in children. Clin Infect Dis 2005; 41: 35–41PubMedCrossRef
9.
Zurück zum Zitat Brook I, Gober AE. Bacteriology of spontaneously draining acute otitis media in children before and after the introduction of pneumococcal vaccination. Pediatr Infect Dis J 2009; 28(7): 640–2PubMedCrossRef Brook I, Gober AE. Bacteriology of spontaneously draining acute otitis media in children before and after the introduction of pneumococcal vaccination. Pediatr Infect Dis J 2009; 28(7): 640–2PubMedCrossRef
10.
Zurück zum Zitat Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estrolate, triple sulfonamide, ampicillin, erythromycin estolate triple sulfonamide, and placebo in 280 patients with acute otitis media under two and one-halfyears of age. Clin Pediatr (Phila) 1972; 11: 205–14CrossRef Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estrolate, triple sulfonamide, ampicillin, erythromycin estolate triple sulfonamide, and placebo in 280 patients with acute otitis media under two and one-halfyears of age. Clin Pediatr (Phila) 1972; 11: 205–14CrossRef
11.
Zurück zum Zitat Kilpi T, Herva E, Kaijalainen T, et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001; 20: 654–62PubMedCrossRef Kilpi T, Herva E, Kaijalainen T, et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life. Pediatr Infect Dis J 2001; 20: 654–62PubMedCrossRef
12.
Zurück zum Zitat Barkai G, Leibovitz E, Givon-Lavi N, et al. Potential contribution by non-typable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009; 28: 466–71PubMedCrossRef Barkai G, Leibovitz E, Givon-Lavi N, et al. Potential contribution by non-typable Haemophilus influenzae in protracted and recurrent acute otitis media. Pediatr Infect Dis J 2009; 28: 466–71PubMedCrossRef
13.
Zurück zum Zitat Veenhoven R, Bogaert D, Uiterwaal RH, et al. Effect of conjugate pneumococcal vaccine followed by polysacharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet 2003; 361: 2189–95PubMedCrossRef Veenhoven R, Bogaert D, Uiterwaal RH, et al. Effect of conjugate pneumococcal vaccine followed by polysacharide pneumococcal vaccine on recurrent acute otitis media: a randomized study. Lancet 2003; 361: 2189–95PubMedCrossRef
14.
Zurück zum Zitat Dagan R, Schneider S, Givon-Lavi N, et al. Failure to achieve early bacterial eradication increases clinical failure rate in acute otitis media in young children. Pediatr Infect Dis J 2008; 27: 200–6PubMedCrossRef Dagan R, Schneider S, Givon-Lavi N, et al. Failure to achieve early bacterial eradication increases clinical failure rate in acute otitis media in young children. Pediatr Infect Dis J 2008; 27: 200–6PubMedCrossRef
15.
Zurück zum Zitat Howie VM, Owen MJ. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. Pediatr Infect Dis J 1987; 6: 989–91PubMedCrossRef Howie VM, Owen MJ. Bacteriologic and clinical efficacy of cefixime compared with amoxicillin in acute otitis media. Pediatr Infect Dis J 1987; 6: 989–91PubMedCrossRef
16.
Zurück zum Zitat Johnson CE, Carlin SA, Super DM, et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22PubMedCrossRef Johnson CE, Carlin SA, Super DM, et al. Cefixime compared with amoxicillin for treatment of acute otitis media. J Pediatr 1991; 119: 117–22PubMedCrossRef
17.
Zurück zum Zitat Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J 2003; 22: 405–12PubMed Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J 2003; 22: 405–12PubMed
18.
Zurück zum Zitat Jacobs MR, Felmingham D, Appelbaum PC, et al., for the Alexander Project Group. The Alexander Project 1998–2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229–46PubMedCrossRef Jacobs MR, Felmingham D, Appelbaum PC, et al., for the Alexander Project Group. The Alexander Project 1998–2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229–46PubMedCrossRef
19.
Zurück zum Zitat Drusano G, Craig W. Relevance of pharmacokinetics and pharmacodynamics in the selection for respiratory tract infections. J Chemother 1997; 9: 38–44PubMed Drusano G, Craig W. Relevance of pharmacokinetics and pharmacodynamics in the selection for respiratory tract infections. J Chemother 1997; 9: 38–44PubMed
20.
Zurück zum Zitat Arguedas A, Dagan R, Pichichero M, et al. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J 2006; 25: 211–8PubMedCrossRef Arguedas A, Dagan R, Pichichero M, et al. A multicenter, open label, double tympanocentesis study of high dose cefdinir in children with acute otitis media at high risk of persistent or recurrent infection. Pediatr Infect Dis J 2006; 25: 211–8PubMedCrossRef
21.
Zurück zum Zitat Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 944–8CrossRef Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 944–8CrossRef
22.
Zurück zum Zitat Jacobs MR, Bajksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 Oral Antimicrobial Agents Based on Pharmacodynamic Parameters: 1997 U.S. Surveillance Study. Antimicrob Agents Chemother 1999; 43: 1901–8PubMed Jacobs MR, Bajksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 Oral Antimicrobial Agents Based on Pharmacodynamic Parameters: 1997 U.S. Surveillance Study. Antimicrob Agents Chemother 1999; 43: 1901–8PubMed
23.
Zurück zum Zitat Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176: 1253–9PubMedCrossRef Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176: 1253–9PubMedCrossRef
24.
Zurück zum Zitat Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43–50PubMedCrossRef Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43–50PubMedCrossRef
25.
Zurück zum Zitat Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19: 1040–5PubMedCrossRef Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19: 1040–5PubMedCrossRef
26.
Zurück zum Zitat Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. Ped Infect Dis J 2001; 20: 260–4CrossRef Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. Ped Infect Dis J 2001; 20: 260–4CrossRef
27.
Zurück zum Zitat Dagan R, Johnson C, McLinn S, et al. Bacteriological and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20: 829–37PubMedCrossRef Dagan R, Johnson C, McLinn S, et al. Bacteriological and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20: 829–37PubMedCrossRef
28.
Zurück zum Zitat Dagan R, Johnson C, McLinn S, et al. Bacteriological and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19: 95–104PubMedCrossRef Dagan R, Johnson C, McLinn S, et al. Bacteriological and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19: 95–104PubMedCrossRef
29.
Zurück zum Zitat Hoberman A, Marchant CD, Kaplan SL. Kinetics and tolerability in children receiving 25 mg/kg once daily. Pediatr Infect Dis J 2005; 24: 525–32PubMedCrossRef Hoberman A, Marchant CD, Kaplan SL. Kinetics and tolerability in children receiving 25 mg/kg once daily. Pediatr Infect Dis J 2005; 24: 525–32PubMedCrossRef
30.
Zurück zum Zitat Marchant CD, Dagan R. Bacteriological efficacy of antimicrobial agents. In: Rosenfeld RM, Bluestone CD, editors. Evidence-based Otitis Media. 2nd edn. Hamilton, Ontario: 2003: 256–67 Marchant CD, Dagan R. Bacteriological efficacy of antimicrobial agents. In: Rosenfeld RM, Bluestone CD, editors. Evidence-based Otitis Media. 2nd edn. Hamilton, Ontario: 2003: 256–67
31.
Zurück zum Zitat Marchant CD, Carlin SA, Johnson CE, et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the “Pollyanna phenomenon”. J Pediatr 1992; 120: 72–7PubMedCrossRef Marchant CD, Carlin SA, Johnson CE, et al. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the “Pollyanna phenomenon”. J Pediatr 1992; 120: 72–7PubMedCrossRef
32.
Zurück zum Zitat American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and management of AOM. Pediatrics 2004; 113: 1451–65CrossRef American Academy of Pediatrics and American Academy of Family Physicians. Diagnosis and management of AOM. Pediatrics 2004; 113: 1451–65CrossRef
Metadaten
Titel
Appropriate Treatment of Acute Otitis Media in the Era of Antibiotic Resistance
verfasst von
Professor Ron Dagan
Publikationsdatum
01.06.2010
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe Sonderheft 1/2010
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/11538720-S0-000000000-00002

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.